Now showing items 1-1 of 1

    • The integration of BRCA testing into oncology clinics. 

      Percival, N; George, A; Gyertson, J; Hamill, M; Fernandes, A; Davies, E; Rahman, N; Banerjee, S (2016-06)
      Purpose The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, ...